{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T04:33:59Z","timestamp":1785731639163,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"European University of Madrid"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.vaccine.2017.10.008","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T07:50:10Z","timestamp":1507881010000},"page":"6395-6403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["BCG immune activation reduces growth and angiogenesis in an in vitro model of head and neck squamous cell carcinoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Carolina","family":"S\u00e1nchez-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyliz Peraza","family":"Cruces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Riestra Ayora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mart\u00edn-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Sanz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2017.10.008_b0005","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1067\/j.cpsurg.2008.10.002","article-title":"Cancer of the head and neck is the sixth most common cancer worldwide","volume":"46","author":"Duvvuri","year":"2009","journal-title":"Curr Probl Surg"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.008_b0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/jca.5112","article-title":"The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas","volume":"4","author":"Koontongkaew","year":"2013","journal-title":"J Cancer"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.008_b0015","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.oraloncology.2013.09.009","article-title":"Promising systemic immunotherapies in head and neck squamous cell carcinoma","volume":"49","author":"Gildener-Leapman","year":"2013","journal-title":"Oral Oncol"},{"issue":"14","key":"10.1016\/j.vaccine.2017.10.008_b0020","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1158\/0008-5472.CAN-08-3465","article-title":"Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer","volume":"69","author":"Bao","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.008_b0025","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.hoc.2015.07.009","article-title":"Immunotherapy for head and neck squamous cell carcinoma","volume":"29","author":"Schoppy","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.008_b0030","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1158\/1078-0432.CCR-07-5126","article-title":"T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease","volume":"14","author":"Bergmann","year":"2008","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.vaccine.2017.10.008_b0035","first-page":"371","article-title":"Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression","author":"Bergmann","year":"2009","journal-title":"Proteins"},{"key":"10.1016\/j.vaccine.2017.10.008_b0040","article-title":"Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients","volume":"10","author":"Bose","year":"2008","journal-title":"Cancer Immun: J Acad Cancer Immunol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00262-008-0520-7","article-title":"Effect of BCG stimulus on proinflammatory cytokine production in laryngeal cancer","volume":"58","author":"Conti-Freitas","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2017.10.008_b0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3181\/00379727-26-4143","article-title":"On the pathological relations between cancer and tuberculosis","volume":"26","author":"Pearl","year":"1928","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.008_b0055","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"issue":"1316\u20131324","key":"10.1016\/j.vaccine.2017.10.008_b0060","first-page":"13","article-title":"Internalization of bacille Calmette-Guerin by bladder tumor cells","volume":"145","author":"Becich","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0065","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bjc.6602026","article-title":"Role of urothelial cells in BCG immunotherapy for superficial bladder cancer","volume":"91","author":"Bevers","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2017.10.008_b0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","article-title":"Flad HD Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall","volume":"144","author":"Bohle","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0075","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-5347(17)39713-6","article-title":"Smyth JF radioimmunoassay detection of interferon-gamma in urine after intravesical BCG therapy","volume":"144","author":"Prescott","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0080","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","article-title":"Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression","volume":"14","author":"Kaempfer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0085","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0090","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-5347(01)62065-2","article-title":"Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?","volume":"161","author":"de Reijke","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0100","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2017.10.008_b0105","article-title":"Bladder cancer immunotherapy: BCG and beyond","volume":"181987","author":"Askeland","year":"2012","journal-title":"Adv Urol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.008_b0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer","volume":"277","author":"Mitsudomi","year":"2010","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.008_b0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5732\/cjc.010.10542","article-title":"Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations","volume":"30","author":"Wykosky","year":"2011","journal-title":"Chin J Cancer"},{"issue":"56","key":"10.1016\/j.vaccine.2017.10.008_b0120","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","article-title":"The EGF receptor family as targets for cancer therapy","volume":"19","author":"Mendelsohn","year":"2000","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.008_b0125","doi-asserted-by":"crossref","first-page":"408","DOI":"10.7326\/0003-4819-117-5-408","article-title":"Autocrine secretion\u201310 years later","volume":"117","author":"Sporn","year":"1992","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.008_b0130","doi-asserted-by":"crossref","first-page":"e75388","DOI":"10.1371\/journal.pone.0075388","article-title":"Expression of angiopoietin-2 and vascular endothelial growth factor receptor-3 correlates with lymph angiogenesis and angiogenesis and affects survival of oral squamous cell carcinoma","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.008_b0135","first-page":"162","article-title":"Three dimensional tumor models for cancer studies","volume":"1","author":"Penfornis","year":"2017","journal-title":"Front Biosci (Elite Ed)"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.008_b0140","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-3083.2008.02072.x","article-title":"Co-culture of head and neck squamous cell carcinoma spheroids with autologous monocytes predicts prognosis","volume":"67","author":"Kross","year":"2008","journal-title":"Scand J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2017.10.008_b0145","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.bjp.0704184","article-title":"High glucose induces cell death of cultured human aortic smooth muscle cells through the formation of hydrogen peroxide","volume":"133","author":"Peir\u00f3","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.008_b0150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/CIRCRESAHA.108.178434","article-title":"BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis","volume":"103","author":"Heinke","year":"2008","journal-title":"Circ Res."},{"key":"10.1016\/j.vaccine.2017.10.008_b0155","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0140-6736(98)07422-4","article-title":"BCG immunotherapy of bladder cancer: 20 years on","volume":"353","author":"Alexandro","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.008_b0160","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archotol.1983.00800220049012","article-title":"The controversial role of BCG in the treatment of squamous cell carcinoma of the head and neck","volume":"109","author":"Medina","year":"1983","journal-title":"Arch Otolaryngol"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.008_b0165","article-title":"Targeting immune regulatory networks to counteract immune suppression in cancer","volume":"4","author":"Camisaschi","year":"2016","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.008_b0170","first-page":"335","article-title":"Mononuclear phagocytes in head and neck squamous cell carcinoma.","volume":"267","author":"Kross","year":"2010","journal-title":"Eur Arch oto-rhino-laryngol: Off J Eur Feder Oto-Rhino-Laryngol Soc (EUFOS): Affil German Soc Oto-Rhino-Laryngol \u2013 Head Neck Surg"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.008_b0175","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1590\/S1806-83242011000500007","article-title":"Borra RC response of peripheral blood mononuclear cells to conditioned medium from cultured oral squamous cell carcinomas","volume":"25","author":"Fran\u00e7a","year":"2011","journal-title":"Braz Oral Res"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.008_b0180","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0030-6665(02)00038-5","article-title":"The molecular biology of laryngeal cancer","volume":"35","author":"Ha","year":"2002","journal-title":"Otolaryngol Clin North Am"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.008_b0185","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/cncr.23615","article-title":"Interleukin-6 predicts recurrence and survival among head and neck cancer patients","volume":"113","author":"Duffy","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.008_b0190","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/jcp.2003.007641","article-title":"Molecular biology of squamous cell carcinoma of the head and neck","volume":"59","author":"Perez-Ordo\u00f1ez","year":"2006","journal-title":"J Clin Pathol"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.008_b0195","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/0959-8049(95)00210-3","article-title":"Cytokine modulation of epidermal growth factor receptor expression on bladder cancer cells is not a major contributor to the antitumour activity of cytokines","volume":"31A","author":"Alexandroff","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2017.10.008_b0200","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00005392-199907000-00072","article-title":"Intravesical bacillus calmette-guerin (BCG) as inducer of tumor-suppressing proteins p53 and p21 Waf1-Cip1 during treatment of superficial bladder cancer","volume":"162","author":"Fontana","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0205","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000283049","article-title":"Are BCG effects against urinary bladder carcinoma cell line T24 correlated with apoptosis in vitro?","volume":"59","author":"Sasaki","year":"1997","journal-title":"Urol Int"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.008_b0210","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.juro.2015.11.073","article-title":"The dose-response relationship of bacillus calmette-gu\u00e9rin and urothelial carcinoma cell biology","volume":"195","author":"Shah","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0215","first-page":"1015","article-title":"Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanisms for bystander effect","volume":"5","author":"Nishizaki","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2017.10.008_b0220","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.1996.14.10.2646","article-title":"Overexpression of p53 protein in a high-risk population of patients with non muscle invasive bladder cancer before and after Bacillus Calmette-Guerin therapy: correlation to clinical outcome","volume":"14","author":"Lacombe","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0225","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0022-5347(01)63839-4","article-title":"P53 status does not predict initial clinical response to Bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors","volume":"159","author":"Pages","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00005392-199907000-00017","article-title":"P53 mutations in bladder tumors inactivate the transactivation of the P21 and BAX genes, and have a predictive value for the clinical outcome after Bacillus Calmette-Guerin","volume":"162","author":"Pfister","year":"1999","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.008_b0235","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.aju.2015.05.001","article-title":"The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette-Guerin","volume":"13","author":"Hegazy","year":"2015","journal-title":"Arab J Urol"},{"key":"10.1016\/j.vaccine.2017.10.008_b0240","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40425-016-0138-9","article-title":"Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients","volume":"4","author":"Sridharan","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.vaccine.2017.10.008_b0245","doi-asserted-by":"crossref","unstructured":"Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, Egan JO, Rhode PR, Parker AS, Chai KX, Wong HC, Rosser CJ. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One (2014) 4;9(6):e96705.","DOI":"10.1371\/journal.pone.0096705"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.008_b0250","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/S0022-5347(05)67620-3","article-title":"BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation","volume":"163","author":"Pavlovich","year":"2000","journal-title":"J Urol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17313737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17313737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T16:36:57Z","timestamp":1570207017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17313737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":50,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0264410X17313737"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCG immune activation reduces growth and angiogenesis in an in vitro model of head and neck squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}